Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-12, 19, 27, 34-37, 39 and 41 are currently pending in the instant application. Applicants have amended claims 1, 9, 12, 19, 27, 34, 35 and 37 in an amendment filed on April 27, 2026. Claims 1-6, 8-10 and 36 are rejected, claims 7, 11, 34, 37, 39 and 41 are objected and claims 12, 19, 27 and 35 are considered allowable in this Office Action.
I. Response to Arguments/Remarks
Applicants’ amendment, filed on April 27, 2026, has overcome all of the pending rejections and objections in the previous Office Action. All previous rejections and objections have been withdrawn.
II. Information Disclosure Statement
The information disclosure statement (IDS) submitted on April 27, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner.
III. Rejection(s)
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless -
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-6, 8-10 and 36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Weiwer, et al. (Bioorg. Med. Chem. Lett. 22 (2012) 1822-1826). The instant invention claims
PNG
media_image1.png
687
827
media_image1.png
Greyscale
PNG
media_image2.png
183
780
media_image2.png
Greyscale
The Weiwer, et al. reference teaches piperazine containing compounds such as
PNG
media_image3.png
149
359
media_image3.png
Greyscale
(See page 1825, table 4) wherein Ar1 and Ar2 are both unsubstituted phenyl; X is piperazine; Y is CO and R is oxazole substituted with methyl and a second substituent (i.e, -NO2). This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
Claims 1-6, 8-9 and 36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Song, et al. (Bioorg. Med. Chem. 16 (2008) 4035-4051). The instant invention claims
PNG
media_image1.png
687
827
media_image1.png
Greyscale
PNG
media_image2.png
183
780
media_image2.png
Greyscale
The Song, et al. reference teaches piperazine containing compounds such as
PNG
media_image4.png
152
190
media_image4.png
Greyscale
PNG
media_image5.png
47
466
media_image5.png
Greyscale
PNG
media_image6.png
40
517
media_image6.png
Greyscale
(See page 4040, table 1) wherein Ar1 and Ar2 are both substituted phenyl with halogen(s); X is piperazine; Y is CO and R is cyclohexyl or cyclobutyl both unsubstituted. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
Claims 1-6, 8-10 and 36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kumar, et al. (European Journal of Medicinal Chemistry 44 (2009) 1223-1229). The instant invention claims
PNG
media_image1.png
687
827
media_image1.png
Greyscale
PNG
media_image2.png
183
780
media_image2.png
Greyscale
The Kumar, et al. reference teaches piperazine containing compounds such as
PNG
media_image7.png
120
143
media_image7.png
Greyscale
PNG
media_image8.png
375
276
media_image8.png
Greyscale
(See page 1225, table 1) wherein Ar1 and Ar2 are both unsubstituted phenyl; X is piperazine; Y is SO2 and R is phenyl substituted or unsubstituted. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
Claims 1-6, 8-10 and 36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Okada, et al. (WO 2011/148888 A1). The instant invention claims
PNG
media_image1.png
687
827
media_image1.png
Greyscale
PNG
media_image2.png
183
780
media_image2.png
Greyscale
The Okada, et al. reference teaches piperazine containing compounds such as
PNG
media_image9.png
151
253
media_image9.png
Greyscale
(See page 1225, table 1) wherein Ar1 and Ar2 are both substituted phenyl with F; X is piperazine; Y is CH2 and R is pyridine substituted with an alkoxycarbonyl. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
Claims 1-6, 8-10 and 36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rotta, et al. (European Journal of Medicinal Chemistry 90 (2015) 436-447). The instant invention claims
PNG
media_image1.png
687
827
media_image1.png
Greyscale
PNG
media_image2.png
183
780
media_image2.png
Greyscale
The Rotta, et al. reference teaches piperazine containing compounds such as
PNG
media_image10.png
112
205
media_image10.png
Greyscale
(See page 1225, table 1) wherein Ar1 and Ar2 are both unsubstituted phenyl; X is piperazine; Y is SO2 and R is unsubstituted phenyl. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
IV. Objections
Dependent Claim Objections
Dependent Claims 7, 11, 37, 39 and 41 are objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim.
Claim Objections
Claim 34 ais objected to because of the following informalities: Claim 34 is missing a period at the end of the claim. Each claim begins with a capital letter and ends with a period (MPEP 608.01 (m)). Claim 34 has structures numbered 4-19 that are small and difficult to read. Applicants are suggested to make these structures larger to overcome the objection. Appropriate correction is required.
V. Conclusion
Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the timing fee set forth in 37 CFR 1.17(p) on April 27, 2026 prompted the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 609.04(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is (571)272-9043. The examiner can normally be reached on M-F 7AM-4PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached on (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Prosecution Insights